This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2002;288:35.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—A cluster of efforts against tuberculosis (TB) had experts at the Fourth World Congress on Tuberculosis sounding optimistic about a disease that still claims 2 million lives each year. The expansion of prevention and control campaigns in China and India, a renewed drive toward an adult vaccine, and the infusion of several hundred million dollars into research and treatment have the world poised for "rapid advances," said Philip Hopewell, MD, a TB researcher at the University of San Francisco School of Medicine.

While those developments bode well, other speakers noted two ominous trends, namely the emergence of TB in Eastern Europe and the 15 states of the former Soviet Union, and the rise of multidrug-resistant strains. Worldwide, some 3% of cases are drug-resistant, but in former Soviet states, which have suffered from economic collapse, that figure reaches as high as 14%. In early June, the World Health . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Minerva
BMJ 2002;325:172-172.
FULL TEXT